Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 15;92(5):399-404.
doi: 10.1097/QAI.0000000000003158. Epub 2023 Jan 3.

Brief Report: Does Menopause Transition Influence Viral Suppression and Adherence in Women Living With HIV?

Anna Hachfeld  1 , Andrew Atkinson  1 , Petra Stute  2 , Alexandra Calmy  3 , Philip E Tarr  4 , Katharine E A Darling  5 , Baharak Babouee Flury  6 , Christian Polli  7 , Leila Sultan-Beyer  8 , Irene A Abela  9   10 , Karoline Aebi-Popp  1 ; Swiss HIV Cohort Study (SHCS)
Affiliations

Brief Report: Does Menopause Transition Influence Viral Suppression and Adherence in Women Living With HIV?

Anna Hachfeld et al. J Acquir Immune Defic Syndr. .

Abstract

Background: Increasing numbers of women living with HIV transition through menopause. It is unclear whether this transition has an impact on treatment adherence, viral suppression, psychiatric comorbidities, or drug use. We aimed at examining adherence and viral suppression during the perimenopausal period and explored the influence of psychiatric comorbidities and active injection drug use (IDU).

Setting: Retrospective Swiss HIV Cohort Study analysis from January 2010 to December 2018.

Methods: We explored perimenopausal and postmenopausal trends of viral blips, low-level viremia, viral failure, adherence, psychiatric comorbidities, and IDU using interrupted time series models.

Results: Rates of depression and psychiatric care increased during perimenopause before decreasing afterward. Negative treatment outcomes such as viral blips, low-level viremia, viral failure, and low adherence steadily declined while transitioning through menopause-this was also true for subgroups of women with depression, psychiatric treatment, and active IDU.

Conclusions: Increased rates of depression and psychiatric care while transitioning through menopause do not result in lower rates of adherence or viral suppression in women living with HIV in Switzerland.

PubMed Disclaimer

Conflict of interest statement

None of the authors has declared a possible conflict of interest related to this study. A.H.'s institution has received travel grants, congress and advisory fees from MSD, ViiV, and Gilead, unrelated to this work. B.B. Flury has undertaken Advisory Boards or ad hoc consultancy for Merck/MSD, Melinta/Menarini, Shionogi, and Pfizer, and has received research grants from Melinta/Menarini unrelated to this work. K.E.A.D.'s institution has received research funding unrelated to this publication from Gilead and offered expert testimony for MSD. P.T.'s institution has received grants, advisory fees, and educational grants from Gilead, MSD, and ViiV outside the submitted work. K.A.-P.’s institution has received travel grants and advisory fees from MSD, Gilead, and ViiV healthcare unrelated to this work. I.A.A. is supported by the ProMedica Foundation.

Figures

FIGURE 1.
FIGURE 1.
Perimenopausal and postmenopausal trends of (A) viral blips (B) low-level viremia (C) viral failures and (D) low adherence. Rate of events over time (black solid), point-wise 95% confidence intervals (gray), LOESS smoother in orange (with 95% confidence intervals shaded), interrupted time series for perimenopause (red) and postmenopause (blue).
FIGURE 2.
FIGURE 2.
Perimenopausal and postmenopausal trends of patients with depression diagnosis (A), psychiatric care (B), active injection drug use (C) during 8 years before and after menopause onset. Rate of events over time (black solid), point-wise 95% confidence intervals (gray), fitted cubic spline (6 knots, orange, gray, and blue) dashed with 95% confidence intervals shaded), interrupted time series for perimenopause (red) and postmenopause (blue).
See this image and copyright information in PMC

References

    1. Hachfeld A, Atkinson A, Stute P, et al. . Women with HIV transitioning through menopause: insights from the Swiss HIV cohort study (SHCS). HIV Med. 2022;23:417–425. - PMC - PubMed
    1. Smit M, Brinkman K, Geerlings S, et al. . Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis. 2015;15:810–818. - PMC - PubMed
    1. Smit M, Cassidy R, Cozzi-Lepri A, et al. . Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study. PLoS One. 2017;12:e0186638. - PMC - PubMed
    1. Van Ommen CE, King EM, Murray MCM. Age at menopause in women living with HIV: a systematic review. Menopause. 2021;28:1428–1436. - PubMed
    1. Ferreira CE, Pinto-Neto AM, Conde DM, et al. . Menopause symptoms in women infected with HIV: Prevalence and associated factors. Gynecol Endocrinol. 2007;23:198–205. - PubMed

Publication types

Substances